PF-05089771

From Wikipedia, the free encyclopedia
Jump to: navigation, search
PF-05089771
PF-05089771.svg
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C18H12Cl2FN5O3S2
Molar mass 500.34 g·mol−1
3D model (Jmol)

PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic.[1][2][3] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.[4]

See also[edit]

References[edit]

  1. ^ McMahon, Stephen B.; Koltzenburg, Martin; Tracey, Irene; Turk, Dennis (March 2013). Wall & Melzack's Textbook of Pain. Elsevier Health Sciences. p. 508. ISBN 0702053740. 
  2. ^ Martz, Lauren (June 2014). "Nav-i-gating antibodies for pain". SciBX: Science-Business eXchange. 7 (23). doi:10.1038/scibx.2014.662. 
  3. ^ Alexandrou, Aristos J.; Brown, Adam R.; Chapman, Mark L.; Estacion, Mark; Turner, Jamie; Mis, Malgorzata A.; Wilbrey, Anna; Payne, Elizabeth C.; Gutteridge, Alex; Cox, Peter J.; Doyle, Rachel; Printzenhoff, David; Lin, Zhixin; Marron, Brian E.; West, Christopher; Swain, Nigel A.; Storer, R. Ian; Stupple, Paul A.; Castle, Neil A.; Hounshell, James A.; Rivara, Mirko; Randall, Andrew; Dib-Hajj, Sulayman D.; Krafte, Douglas; Waxman, Stephen G.; Patel, Manoj K.; Butt, Richard P.; Stevens, Edward B. (6 April 2016). "Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release". PLOS ONE. 11 (4): e0152405. doi:10.1371/journal.pone.0152405. ISSN 1932-6203. PMC 4822888Freely accessible. PMID 27050761. 
  4. ^ Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Storer, R. Ian; Swain, Nigel A. (15 August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–3699. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.